1st International Workshop on HIV Persistence during Therapy. St. Martin, December 10-12, 2003.
HIV-pathogenesis involves both pathogenic effects on some HIV infected cells and indirect effects on uninfected bystander cells. It has been self-evident for almost 20 years that reducing the amount of virus is beneficial to infected patients, as reduction in HIV-RNA viral load blocks direct as well as indirect pathogenic effects of HIV-1. However, eradication has not been achieved. As during suppressive HAART (highly active antiretroviral therapy) a great variety of cells can become HIV-reservoirs, they feature as numerous potential targets for new therapeutic approaches as for instance immune-based therapy.
Tossing
Gudrun
G
Essex Pharma GmbH, Tannenstrasse 15/15a, D-42653 Solingen, Germany. gudrun.tossing@essex.de
D023241:Antiretroviral Therapy, Highly Active; D004493:Education; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000472:pathogenicity / Q000502:physiology*; D006801:Humans; D017735:Virus Latency / Q000187:drug effects / Q000502:physiology*; D014779:Virus Replication / Q000187:drug effects / Q000502:physiology*